Understand the source comparison
LL-37 Protocol Comparison: Antimicrobial vs Immune Modulation Applications
Before you use LL-37 for antimicrobial protocol, understanding the application-specific differences in dosing, timing, and endpoints clarifies which framework matches your research objectives. Direct Antimicrobial (Bacterial Challenge Models) 10–20mg per dose
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before you use LL-37 for antimicrobial protocol, understanding the application-specific differences in dosing, timing, and endpoints clarifies which framework matches your research objectives.
- Direct Antimicrobial (Bacterial Challenge Models)
- 10–20mg per dose
- Intravenous or intraperitoneal
- Single dose or every 24 hours × 3–5 days
- Membrane disruption via electrostatic binding to LPS
- Bacterial colony counts, MIC values, survival rates in sepsis models
- Best for rapid-onset antimicrobial effect; requires higher doses to achieve systemic bactericidal concentrations
- Immune Modulation (Chemotaxis, Wound Healing)
- 5–10mg per dose
- Subcutaneous
- Every 48–72 hours × 2–4 weeks
- FPRL1 receptor activation, neutrophil chemotaxis, cytokine modulation
- IL-6, TNF-α, neutrophil migration assays, wound closure rates
- Lower doses sufficient; focuses on signaling rather than bactericidal concentration; longer timelines required for measurable immune response
- Combination (Antimicrobial + Immunomodulation)
- 10–15mg per dose
- Subcutaneous or intravenous
- Every 48 hours × 1–2 weeks
- Dual: membrane disruption + immune activation
- Bacterial load reduction + cytokine profiles + histological inflammation scores
- Requires balanced dosing to avoid overwhelming immune activation; monitoring both antimicrobial and inflammatory markers essential